Former Salesforce Executive will be Responsible for Accelerating Growth in the Canadian Market PLEASANTON, Calif., May 20, 2025 /PRNewswire/ -- Workday, Inc. (NASDAQ: WDAY), the AI platform for managing people, money, and agents, today announced the appointment of Edward Charter as country leader for Canada. Charter brings with him over 20 years of experience in technology business development and sales leadership throughout North America. He spent the last 18 years in various leadership roles at Salesforce ...

Multi-centre, blinded, randomized placebo-controlled investigator initiated study, to be led by Dr. Hance Clarke and conducted at University Health Network For more information about Avicanna, visit our website or contact Ivana Maric by email at info@avicanna.com. TORONTO, May 20, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-base ...

Edison, New Jersey, May 19, 2025 (GLOBE NEWSWIRE) -- TOFUTTI BRANDS INC. (OTCQB Symbol: TOFB) issued its results for the fiscal quarter ended March 29, 2025 today. Net sales for the thirteen weeks ended March 29, 2025 decreased by $621,000, or 28%, from net sales of $2,212,000 for the thirteen weeks ended March 30, 2024 to $1,591,000 for the thirteen weeks ended March 29, 2025. Sales of our vegan cheese products decreased to $1,373,000 in the thirteen weeks ended March 29, 2025 from $1,809,000 in the thirte ...

Core Insights - CRISPR Therapeutics and Sirius Therapeutics have formed a strategic partnership to co-develop and commercialize SRSD107, a long-acting Factor XI (FXI) small interfering RNA (siRNA) for thromboembolic disorders [1][2] - SRSD107 has shown promising results in Phase 1 clinical trials, achieving over 93% reduction in FXI activity and more than twofold increase in activated partial thromboplastin time (aPTT), with effects lasting up to 6 months post-dosing [1][3] - The collaboration includes an upfront payment of $25 million in cash and $70 million in equity from CRISPR to Sirius, with a 50-50 cost and profit-sharing structure for SRSD107 [1][8] Company Overview - CRISPR Therapeutics is focused on creating transformative gene-based medicines and has a diverse portfolio across various disease areas, including cardiovascular diseases [10] - Sirius Therapeutics is a clinical-stage biotech company developing innovative siRNA therapies, with SRSD107 being its most advanced product targeting thromboembolic disorders [17][18] Clinical Development - The clinical program for SRSD107 includes two Phase 1 trials demonstrating safety and robust pharmacodynamic effects, with a Phase 2 trial planned to evaluate its efficacy in preventing venous thromboembolism (VTE) in total knee arthroplasty patients [3][7] - SRSD107 is designed to selectively inhibit FXI, aiming to reduce thrombotic events while minimizing bleeding risks, offering a differentiated approach compared to existing therapies [2][16] Market Potential - Thromboembolic disorders are a significant global health issue, affecting millions and representing a substantial unmet medical need [2][15] - The addressable patient population for SRSD107 includes those with atrial fibrillation, venous thromboembolism, cancer-associated thrombosis, and other conditions where existing therapies pose bleeding risks [2][3]

Company Overview - Marimekko Corporation is a Finnish lifestyle design company known for its original prints and colors, offering a diverse product portfolio that includes high-quality clothing, bags, accessories, and home décor items [2] - Founded in 1951, Marimekko established a strong identity through its unique printed fabrics [2] - The company reported net sales of EUR 183 million in 2024, with a comparable operating profit margin of 17.5 percent [2] - Marimekko operates approximately 170 stores globally and serves customers in 39 countries through its online store [2] - The key markets for Marimekko include Northern Europe, the Asia-Pacific region, and North America [2] - The company employs around 480 people and its shares are listed on Nasdaq Helsinki Ltd [2] Recent Transactions - On 15 April 2025, Marimekko's Annual General Meeting resolved that about 40 percent of the annual remuneration for Board members will be paid in shares acquired from the market [1] - Marianne Vikkula, a member of the Board, received a share-based incentive of 909 shares on 16 May 2025, with a unit price of 0.00 EUR [1]

Company Overview - Marimekko Corporation is a Finnish lifestyle design company known for its original prints and colors [2] - The company offers a diverse product portfolio including high-quality clothing, bags, accessories, and home décor items [2] - Founded in 1951, Marimekko has established a strong identity through its unique printed fabrics [2] Financial Performance - In 2024, Marimekko's net sales reached EUR 183 million [2] - The comparable operating profit margin for the same year was 17.5 percent [2] Market Presence - Marimekko operates approximately 170 stores globally and has an online store serving customers in 39 countries [2] - Key markets for the company include Northern Europe, the Asia-Pacific region, and North America [2] - The company employs around 480 people [2] Recent Transactions - On May 16, 2025, Carol Chen, a member of the Board, received a share-based incentive of 909 shares, with a unit price of 0.00 EUR [1] - Approximately 40 percent of the annual remuneration for Board members will be paid in Marimekko shares acquired from the market [1]

Understanding Data Security Risk 2025 Survey Report © 2025 Cloud Security Alliance – All Rights Reserved. You may download, store, display on your computer, view, print, and link to the Cloud Security Alliance at https://cloudsecurityalliance.org subject to the following: (a) the draft may be used solely for your personal, informational, non- commercial use; (b) the draft may not be modified or altered in any way; (c) the draft may not be redistributed; and (d) the trademark, copyright or other notices may ...

Core Insights - Intellia Therapeutics announced positive two-year follow-up data from the Phase 1 trial of investigational nexiguran ziclumeran (nex-z) for hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN) [1][2] - The data presented at the 2025 Peripheral Nerve Society Annual Meeting indicates that a single dose of nex-z leads to significant reductions in serum TTR levels and improvements in neuropathic impairment measures [2][5] ATTRv-PN Results - In the dose-escalation portion (N=15), the mean Neuropathy Impairment Score (NIS) improved by -2.0 at Month 12 and -4.5 at Month 24 [4] - In the dose expansion portion (N=21), the mean NIS improved by -2.1 at Month 12 and -5.2 at Month 24 [4] - The overall mean change in modified NIS +7 (mNIS+7) was -0.6 at Month 12 and -8.5 at Month 24 [4] - Among patients previously on patisiran, the mean mNIS+7 change was -6.3 at Month 12 and -6.5 at Month 24 [4] - The Norfolk Quality of Life-Diabetic Neuropathy (QoL-DN) score improved by -3.5 at Month 12 and -8.5 at Month 24 [4] - Neurofilament light chain (NfL) showed a reduction of -8.6% at Month 12 [4] Safety and Tolerability - Nex-z demonstrated generally favorable safety and tolerability with no new drug-related adverse events reported during the follow-up period [5][7] - The most common treatment-related adverse events were mild to moderate infusion-related reactions, which did not lead to discontinuations [7] Clinical Program and Future Prospects - The ongoing Phase 1 trial is a multi-center study evaluating nex-z in adults with hereditary ATTR amyloidosis [8] - The Phase 3 MAGNITUDE-2 trial is designed to measure clinical outcomes and evaluate the efficacy of a single dose of nex-z, with a potential biologics license application submission by 2028 [5][9] - Nex-z is based on CRISPR technology and aims to be the first one-time treatment for ATTR amyloidosis by inactivating the TTR gene [10]

Shares of Carnival Corporation & plc (CCL) have been cruising higher, surging 28.7% in the past month compared with the Zacks Leisure and Recreation Services industry’s 23.2% growth. Over the same timeframe, the stock has outperformed the S&P 500’s growth of 11.6%.Carnival’s recent stock surge has been supported by a combination of strong earnings performance, improved macro sentiment, and growing institutional interest. Investor optimism has also grown amid easing trade tensions between the United States a ...

Group 1 - The article discusses the analytical approach of Stephen, who combines clinical insight with valuation methods to analyze healthcare and tech stocks [1] - Stephen specializes in scenario-based DCF modeling, sensitivity analysis, and Monte Carlo simulations to identify asymmetric risk-reward opportunities [1] - The focus is on translating complex scientific and market dynamics into actionable investment theses [1] Group 2 - The article emphasizes the importance of independent verification of information and conducting thorough research before making investment decisions [3] - It highlights that past performance is not indicative of future results and that no specific investment recommendations are provided [4]